Topiroxostat

Topiroxostat
Clinical data
Trade names	Topiloric, Uriadec
ATC code	None;
Legal status
Legal status	Approved in Japan;
Identifiers
	IUPAC name 4-[5-(4-Pyridinyl)-1H-1,2,4-triazol-3-yl]-2-pyridinecarbonitrile;
CAS Number	577778-58-6;
PubChem CID	5288320;
ChemSpider	4450517;
UNII	0J877412JV;
CompTox Dashboard (EPA)	DTXSID80206462 ;
Chemical and physical data
Formula	C13H8N6
Molar mass	248.249 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CN=CC=C1C2=NC(=NN2)C3=CC(=NC=C3)C#N;
	InChI InChI=1S/C13H8N6/c14-8-11-7-10(3-6-16-11)13-17-12(18-19-13)9-1-4-15-5-2-9/h1-7H,(H,17,18,19); Key:UBVZQGOVTLIHLH-UHFFFAOYSA-N;

Topiroxostat (INN; trade names Topiloric, Uriadec) is a drug for the treatment of gout and hyperuricemia.^[1] It was approved for use in Japan in June 2013.^[1]

Topiroxostat is a xanthine oxidase inhibitor which reduces serum urate levels.^[2]

Synthesis

4-Cyanopyridine [100-48-1] and 2-cyanoisonicotinic acid hydrazide [135048-32-7].

References

^ ^a ^b "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22. {{cite journal}}: Cite journal requires |journal= (help)
^ Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. (December 2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. 18 (6): 876–84. doi:10.1007/s10157-014-0935-8. PMC 4271138. PMID 24448692.
^ EP1471065 idem Hiroshi Nakamura, et al. WO 2003064410 (Fuji Yakuhin Co Ltd).

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

[pmda-1] "New Drugs FY2013" (PDF). Pharmaceuticals and Medical Devices Agency, Japan. Archived from the original (PDF) on 2014-02-22. {{cite journal}}: Cite journal requires |journal= (help)

[2] Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. (December 2014). "Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout". Clinical and Experimental Nephrology. 18 (6): 876–84. doi:10.1007/s10157-014-0935-8. PMC 4271138. PMID 24448692.

[3] EP1471065 idem Hiroshi Nakamura, et al. WO 2003064410 (Fuji Yakuhin Co Ltd).

[1]

[2]

[3]